Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI-Powered ultrasound aims to solve heart diagnosis dilemma

NCT ID NCT07436299

Diagnosis Sponsor: Oslo University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study will test new ultrasound techniques, combined with artificial intelligence, to more accurately measure heart filling pressure in patients who have both heart failure and atrial fibrillation. Current methods are unreliable for these patients, making diagnosis and treatment difficult. Researchers will enroll 400 participants from multiple hospitals to develop and validate a better diagnostic tool, with the goal of predicting who is at highest risk for hospitalization or death.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with atrial fibrillation undergoing clinically indicated right or left heart catheterization.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Atrial fibrillation (paroxysmal, persistent, or permanent) * Scheduled for RHC or LHC for clinical reasons * Able to undergo echocardiography and invasive pressure measurement within 8 hours * No cardiovascular medication changes between echo and catheterization * Written informed consent provided Exclusion Criteria: * Mitral stenosis or mitral annular calcification causing severe functional stenosis * Severe mitral or severe tricuspid regurgitation * Prosthetic mitral valve * Atrial fibrillation with rapid ventricular response \>120 bpm * Suboptimal echocardiographic imaging * Conditions rendering PCWP or LVEDP unreliable * Pregnant women * Complex congenital heart disease * LV assist device and patients with severe non-cardiac disease with poor prognosis * Cardiac transplant patients * End-stage liver disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF) Heart failure (HF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium

    NOT_YET_RECRUITING

    Aalst, 9300, Belgium

  • Carol Davila University of Medicine and Pharmacy

    NOT_YET_RECRUITING

    Bucharest, 020021, Romania

  • Catholic University of Leuven

    NOT_YET_RECRUITING

    Leuven, 3000, Belgium

  • Cleveland Clinic

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Department of Cardiovascular Sciences, University of Birmingham

    NOT_YET_RECRUITING

    Birmingham, United Kingdom

  • Division of Cardiovascular & Pulmonary Diseases, Oslo University Hospital

    RECRUITING

    Oslo, Oslo, 0424, Norway

  • Ehime University

    NOT_YET_RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • King's College

    NOT_YET_RECRUITING

    London, WC2R2LS, United Kingdom

  • Laboratory Signal Processing and Image, Department of Cardiology

    NOT_YET_RECRUITING

    Rennes, 35033, France

  • Methodist DeBakey Heart and Vascular Center

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Nagoya City University Graduate School of Medical Sciences

    NOT_YET_RECRUITING

    Nagoya, Aichi-ken, 467-8601, Japan

  • Service de Cardiologie, Hôpitaux Universitaires de Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67091, France

  • The Department of Cardiology at the Ljubljana University Medical Centre

    NOT_YET_RECRUITING

    Ljubljana, SI-1525, Slovenia

  • University of Auckland

    NOT_YET_RECRUITING

    Auckland, Auckland, 1010, New Zealand

  • Yonsei University College of Medicine

    NOT_YET_RECRUITING

    Seoul, Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.